Toxicological Centre, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.
Toxicological Centre, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.
Chemosphere. 2019 Oct;233:590-596. doi: 10.1016/j.chemosphere.2019.05.280. Epub 2019 Jun 4.
Several regulatory offices called for the phase-out of di (2-ethylhexyl) phthalate (DEHP) in medical devices if safer alternatives are available. In medical devices, the occurrence of alternative plasticizers (APs) is widely variable among types of devices. However, plasticizer use is constantly evolving, as there is no reference to guide manufacturers in the choice and amount to be integrated into their products. As intensive care unit (ICU) patients need numerous indwelling plastic devices during their treatment, we hypothesized that these patients are exposed to APs and phosphate flame retardants and plasticizers (PFRs). Urinary metabolites of APs and PFRs were analyzed in the urine of adult ICU patients (n = 24) over a time period of four days. Our results show that adult ICU patients are exposed to PFRs as well as to APs concentrations were much lower compared to the levels of DEHP metabolites in the same samples. However, significantly higher than in controls (n = 15) this exposure resulted in detectable urinary levels in almost every patient and at every studied time point. Increasing temporal trends were observed for several metabolites from admission until day 3 at ICU. The use of specific medical devices, such as continuous venovenous hemofiltration (CVVH) and extracorporeal membrane oxygenation (ECMO), was associated with an increase in urinary concentrations for several PFR metabolites, despite the lack of information on the presence of these plasticizer chemicals in such medical devices. Further research into the possibly toxic effects of these chemicals released from medical devices is urgently needed.
一些监管机构呼吁,如果有更安全的替代品,应逐步淘汰医疗器械中的邻苯二甲酸二(2-乙基己基)酯(DEHP)。在医疗器械中,替代增塑剂(APs)的出现因器械类型而广泛不同。然而,增塑剂的使用在不断发展,因为没有参考资料来指导制造商选择和确定要整合到产品中的数量。由于重症监护病房(ICU)患者在治疗过程中需要使用大量留置塑料设备,我们假设这些患者会接触到 APs 和磷酸酯阻燃剂和增塑剂(PFRs)。我们分析了 24 名成年 ICU 患者在四天时间内的尿液中的 APs 和 PFRs 代谢物。我们的结果表明,成年 ICU 患者暴露于 PFRs 以及 APs 浓度远低于同一样本中 DEHP 代谢物的水平。然而,与对照组(n=15)相比,这种暴露导致几乎每个患者在每个研究时间点都能检测到可检测的尿液水平。从 ICU 入院到第 3 天,观察到几种代谢物的时间趋势增加。尽管缺乏关于这些医疗器械中存在这些增塑剂化学物质的信息,但使用特定的医疗器械,如连续静脉-静脉血液滤过(CVVH)和体外膜氧合(ECMO),与几种 PFR 代谢物的尿液浓度增加有关。迫切需要进一步研究这些从医疗器械中释放的化学物质可能产生的毒性影响。